Alemtuzumab and intrathecal methotrexate failed in the therapy of Rasmussen encephalitis

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F17%3A10373632" target="_blank" >RIV/00216208:11130/17:10373632 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064203:_____/17:10373632

Výsledek na webu

<a href="https://doi.org/10.1212/NXI.0000000000000354" target="_blank" >https://doi.org/10.1212/NXI.0000000000000354</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1212/NXI.0000000000000354" target="_blank" >10.1212/NXI.0000000000000354</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Alemtuzumab and intrathecal methotrexate failed in the therapy of Rasmussen encephalitis

Popis výsledku v původním jazyce

Rasmussen encephalitis (RE) is a rare but devastating unihemispheric brain disorder that often affects children. The clinical picture is characterized by intractable focal epilepsy and progressive decline of functions associated with the affected hemisphere.2 Despite its known inflammatory background and T-cell involvement, immunotherapy appears to slow rather than halt disease progression, and hemispherotomy appears to be the only solution for intractable epilepsy. A potential early therapeutic window has been suggested, and new therapeutic agents have become available.1 A monoclonal antibody targeting CD52 that leads to long-term depletion of lymphocytes (alemtuzumab) has previously been considered as a possible treatment option for RE, but clinical data are limited.

Název v anglickém jazyce

Alemtuzumab and intrathecal methotrexate failed in the therapy of Rasmussen encephalitis

Popis výsledku anglicky

Rasmussen encephalitis (RE) is a rare but devastating unihemispheric brain disorder that often affects children. The clinical picture is characterized by intractable focal epilepsy and progressive decline of functions associated with the affected hemisphere.2 Despite its known inflammatory background and T-cell involvement, immunotherapy appears to slow rather than halt disease progression, and hemispherotomy appears to be the only solution for intractable epilepsy. A potential early therapeutic window has been suggested, and new therapeutic agents have become available.1 A monoclonal antibody targeting CD52 that leads to long-term depletion of lymphocytes (alemtuzumab) has previously been considered as a possible treatment option for RE, but clinical data are limited.

Druh

O - Ostatní výsledky

CEP obor

—

OECD FORD obor

30109 - Pathology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů